Red Cell Distribution Width (RDW) in Complete Blood Count
RDW is a standard CBC parameter that quantifies the variation in red blood cell size (anisocytosis), traditionally used for differential diagnosis of anemias but now recognized as a powerful prognostic marker for mortality and adverse outcomes across multiple disease states.
What RDW Measures
RDW reflects the degree of heterogeneity in erythrocyte volume 1. It is reported as:
- RDW-CV (coefficient of variation): Most commonly used, with normal values typically <14-15%
- RDW-SD (standard deviation): May offer superior predictive capability 2
Higher RDW values indicate greater variation in red blood cell sizes, representing disrupted erythrocyte homeostasis 1.
Traditional Diagnostic Role
Anemia Evaluation
- Microcytic anemias: RDW helps differentiate iron deficiency (elevated RDW) from thalassemia trait (normal RDW) 3
- Two-population phenomenon: Elevated RDW in female carriers of X-linked sideroblastic anemia reflects the presence of two distinct erythrocyte populations due to X-inactivation 4
- Normocytic/normochromic anemia: In CKD patients, RDW combined with MCV helps identify underlying causes beyond erythropoietin deficiency 5
The anemia of CKD is typically normochromic and normocytic; abnormalities in RDW or MCV should prompt investigation for iron, folate, or B12 deficiency, or inherited hemoglobin synthesis disorders 5.
Prognostic Significance Beyond Anemia
Cardiovascular Disease
- Mortality prediction: Elevated RDW independently predicts all-cause mortality (HR 1.46,95% CI 1.31-1.63) and cardiovascular mortality (HR 1.66,95% CI 1.33-2.07) in patients undergoing PCI 6
- Heart failure: RDW >15.21% increases all-cause mortality risk (OR 1.84,95% CI 1.31-2.57) compared to RDW 14.1-15.20% 7
- Pediatric congenital heart disease: Higher RDW independently predicts cardiovascular events in school-age children, particularly those with Fontan circulation 8
Mechanism of Cardiovascular Risk
RDW >14.0% is associated with decreased red blood cell deformability 9. This impairs microcirculatory blood flow, potentially causing tissue hypoxia and explaining the increased cardiovascular event risk 9.
Cancer Prognosis
In colorectal cancer, elevated preoperative RDW independently predicts:
- Worse overall survival (HR 1.27 for RDW-CV; HR 1.89 for RDW-SD)
- Inferior disease-free survival (HR 1.16)
- Stronger association in patients without neoadjuvant therapy (HR 1.64) 2
General Population Risk
RDW serves as a strong independent risk factor for death in the general population 1. Elevated RDW predicts adverse outcomes in:
- Venous thromboembolism
- Diabetes
- Community-acquired pneumonia
- COPD
- Liver and kidney failure
- Critical illness 1
Underlying Pathophysiology
The mechanisms explaining RDW's broad prognostic value remain incompletely understood but likely involve 1:
- Impaired erythropoiesis: Shortened telomere length, altered erythropoietin function
- Abnormal RBC survival: Erythrocyte fragmentation, decreased deformability
- Metabolic derangements: Oxidative stress, inflammation, poor nutritional status, dyslipidemia, hypertension
Inflammation has been hypothesized but not definitively established as the primary mechanism 10.
Clinical Pitfalls and Caveats
- Analytical variability: RDW assessment may be affected by demographic factors and laboratory methods 1
- Hemoglobin preferred over hematocrit: Hemoglobin is more reproducible and unaffected by storage time or serum glucose 5
- Context matters: While RDW has high negative predictive value, it should not be interpreted in isolation
- Threshold effects: The RDW >14.0% threshold appears clinically significant for deformability 9, while >15.21% marks high mortality risk in heart failure 7
Practical Application
When evaluating a CBC, assess RDW in conjunction with MCV and clinical context:
- Low MCV + elevated RDW → likely iron deficiency
- Low MCV + normal RDW → consider thalassemia trait
- Normal/high MCV + elevated RDW → investigate B12/folate deficiency, hemolysis, or mixed deficiencies
- Any elevated RDW → consider as prognostic marker for adverse outcomes, particularly in cardiovascular disease, cancer, or critical illness